Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
May 8, 2025
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News on the need to fix the Inflation Reduction Act’s (IRA) “pill penalty.” The pill penalty refers to a provision in the IRA that allows Medicare to impose government drug negotiations for small-molecule drugs (like pills and tablets) years sooner than for large-molecule drugs (biologics). Cullilmore notes that there are times when government interventions create unanticipated negative consequences. Such is the case with this IRA policy.
Recent News
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
